Lys503
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys503  -  Myb (human)

Site Information
EDLQDVIkQESDESG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 486351

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 1 ) , immunoprecipitation ( 1 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
leukemia ( 1 ) , T cell leukemia ( 1 )
Relevant cell line - cell type - tissue:

Downstream Regulation
Effects of modification on Myb:
intracellular localization ( 1 )
Effects of modification on biological processes:
transcription, inhibited ( 1 )

References 

1

Dahle Ø, et al. (2003) Transactivation properties of c-Myb are critically dependent on two SUMO-1 acceptor sites that are conjugated in a PIASy enhanced manner. Eur J Biochem 270, 1338-48
12631292   Curated Info